Cargando…

Massively parallel sequencing fails to detect minor resistant subclones in tissue samples prior to tyrosine kinase inhibitor therapy

BACKGROUND: Personalised medicine and targeted therapy have revolutionised cancer treatment. However, most patients develop drug resistance and relapse after showing an initial treatment response. Two theories have been postulated; either secondary resistance mutations develop de novo during therapy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heydt, Carina, Kumm, Niklas, Fassunke, Jana, Künstlinger, Helen, Ihle, Michaela Angelika, Scheel, Andreas, Schildhaus, Hans-Ulrich, Haller, Florian, Büttner, Reinhard, Odenthal, Margarete, Wardelmann, Eva, Merkelbach-Bruse, Sabine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4404105/ https://www.ncbi.nlm.nih.gov/pubmed/25886408 http://dx.doi.org/10.1186/s12885-015-1311-0

Ejemplares similares

Comparison of Pre-Analytical FFPE Sample Preparation Methods and Their Impact on Massively Parallel Sequencing in Routine Diagnostics
por: Heydt, Carina, et al.
Publicado: (2014)

FGFR2 is overexpressed in myxoid liposarcoma and inhibition of FGFR signaling impairs tumor growth in vitro
por: Künstlinger, Helen, et al.
Publicado: (2015)

MET Gene Copy Number Alterations and Expression of MET and Hepatocyte Growth Factor Are Potential Biomarkers in Angiosarcomas and Undifferentiated Pleomorphic Sarcomas
por: Schmitz, Katja, et al.
Publicado: (2015)

qPCR in gastrointestinal stromal tumors: Evaluation of reference genes and expression analysis of KIT and the alternative receptor tyrosine kinases FLT3, CSF1-R, PDGFRB, MET and AXL
por: Fassunke, Jana, et al.
Publicado: (2010)

Overview of Molecular Detection Technologies for MET in Lung Cancer
por: Heydt, Carina, et al.
Publicado: (2023)

Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations
por: Ihle, Michaela Angelika, et al.
Publicado: (2014)

Use of the GeneReader NGS System in a clinical pathology laboratory: a comparative study
por: Koitzsch, Ulrike, et al.
Publicado: (2017)

Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors
por: Wagener-Ryczek, Svenja, et al.
Publicado: (2020)

A subset of gastrointestinal stromal tumors previously regarded as wild-type tumors carries somatic activating mutations in KIT exon 8 (p.D419del)
por: Huss, Sebastian, et al.
Publicado: (2013)

Expression of cell cycle regulators and frequency of TP53 mutations in high risk gastrointestinal stromal tumors prior to adjuvant imatinib treatment
por: Ihle, Michaela Angelika, et al.
Publicado: (2018)

Utility of different massive parallel sequencing platforms for mutation profiling in clinical samples and identification of pitfalls using FFPE tissue
por: FASSUNKE, JANA, et al.
Publicado: (2015)

Genetic instability and recurrent MYC amplification in ALK‐translocated NSCLC: a central role of TP53 mutations
por: Alidousty, Christina, et al.
Publicado: (2018)

HR23b expression is a potential predictive biomarker for HDAC inhibitor treatment in mesenchymal tumours and is associated with response to vorinostat
por: Angelika Ihle, Michaela, et al.
Publicado: (2016)

Biomarker MET in der Tumorpathologie
por: Ihle, Michaela Angelika, et al.
Publicado: (2023)

Deep learning for sensitive detection of Helicobacter Pylori in gastric biopsies
por: Klein, Sebastian, et al.
Publicado: (2020)

PIK3CA mutations in non-small cell lung cancer (NSCLC): Genetic heterogeneity, prognostic impact and incidence of prior malignancies
por: Scheffler, Matthias, et al.
Publicado: (2014)

Comparison of in situ and extraction-based methods for the detection of MET amplifications in solid tumors
por: Heydt, Carina, et al.
Publicado: (2019)

Analysis of tumor mutational burden: correlation of five large gene panels with whole exome sequencing
por: Heydt, Carina, et al.
Publicado: (2020)

Pitfalls in mutational testing and reporting of common KIT and PDGFRA mutations in gastrointestinal stromal tumors
por: Merkelbach-Bruse, Sabine, et al.
Publicado: (2010)

c-myc copy number gain is a powerful prognosticator of disease outcome in cervical dysplasia
por: Kübler, Kirsten, et al.
Publicado: (2014)

ALK(G1269A) mutation as a potential mechanism of acquired resistance to crizotinib in an ALK-rearranged inflammatory myofibroblastic tumor
por: Michels, Sebastian Y. F., et al.
Publicado: (2017)

Mismatch Repair Deficiency and Somatic Mutations in Human Sinonasal Tumors
por: Hieggelke, Lena, et al.
Publicado: (2021)

Copy number variations in atypical fibroxanthomas and pleomorphic dermal sarcomas
por: Helbig, Doris, et al.
Publicado: (2017)

Genomic Characterization of TP53–Wild-Type Esophageal Carcinoma()
por: Quaas, Alexander, et al.
Publicado: (2018)

Molecular Characteristics of Radon Associated Lung Cancer Highlights MET Alterations
por: Gamerith, Gabriele, et al.
Publicado: (2022)

Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer
por: Kron, A, et al.
Publicado: (2018)

KRAS mutation in papillary fibroelastoma: a true cardiac neoplasm?
por: Wittersheim, Maike, et al.
Publicado: (2017)

ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability
por: Scheffler, Matthias, et al.
Publicado: (2015)

Alterations in ERBB2 and BRCA and microsatellite instability as new personalized treatment options in small bowel carcinoma
por: Quaas, Alexander, et al.
Publicado: (2019)

Comparison of the genomic background of MET-altered carcinomas of the lung: biological differences and analogies
por: Castiglione, Roberta, et al.
Publicado: (2018)

Implementing TMB measurement in clinical practice: considerations on assay requirements
por: Büttner, Reinhard, et al.
Publicado: (2019)

Overcoming EGFR(G724S)-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors
por: Fassunke, Jana, et al.
Publicado: (2018)

Biomarkers for Homologous Recombination Deficiency in Cancer
por: Wagener-Ryczek, Svenja, et al.
Publicado: (2021)

Subclonal heterogeneity and evolution in breast cancer
por: Mavrommati, Ioanna, et al.
Publicado: (2021)

Accurate Identification of Subclones in Tumor Genomes
por: Ahmadinejad, Navid, et al.
Publicado: (2022)

Subclones in B-lymphoma cell lines: isogenic models for the study of gene regulation
por: Quentmeier, Hilmar, et al.
Publicado: (2016)

Somatic alterations in circulating cell-free DNA of oesophageal carcinoma patients during primary staging are indicative for post-surgical tumour recurrence
por: Pasternack, Helen, et al.
Publicado: (2018)

LSD1 modulates the non-canonical integrin β3 signaling pathway in non-small cell lung carcinoma cells
por: Lim, So-Young, et al.
Publicado: (2017)

Author Correction: LSD1 modulates the non-canonical integrin β3 signaling pathway in non-small cell lung carcinoma cells
por: Lim, So-Young, et al.
Publicado: (2018)

SQSTM1/p62 promotes miR-198 loading into extracellular vesicles and its autophagy-related secretion
por: Yu, Xiaojie, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kb3s9quu3i2drhssrq89q9068h